Moderna , Inc. (NASDAQ:MRNA) director Noubar Afeyan has sold a significant portion of his holdings in the company, according to recent filings. The transactions, which took place on June 18, 2024, involved the sale of company stock worth over $2 million.
The sales were conducted at varying prices, with the weighted average price of the shares ranging from $132.2245 to $136.92. The transactions were executed in multiple batches, with prices for individual shares sold in a range from as low as $131.71 to as high as $136.92. In total, the director disposed of shares amounting to approximately $2,003,561 in value.
Noubar Afeyan, who serves as a director at Moderna, has been associated with the company through its growth phases. The sales were carried out under a pre-arranged trading plan known as Rule 10b5-1, which was adopted on February 27, 2023, and later amended on November 7, 2023. Such plans allow company insiders to sell stocks at predetermined times to avoid any potential accusations of trading on non-public, material information.
The specific number of shares sold at each price point within the ranges provided has not been disclosed in the filing. However, Afeyan has committed to offering full details to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request.
Following these transactions, Afeyan still holds a substantial number of shares in Moderna directly and indirectly. The indirect holdings are through entities such as Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc., where Afeyan's pecuniary interest is noted, but he disclaims beneficial ownership except to the extent of that interest.
Moderna, headquartered in Cambridge, Massachusetts, is well-known for its role in developing mRNA-based vaccines and therapeutics. The company's stock performance and insider transactions are closely watched by investors for insights into executive sentiment and potential future performance.
As of the date of the filing, Noubar Afeyan's direct holdings in Moderna, following the sale, stand at 2,299,015 shares, with additional indirect holdings through various funds and entities.
In other recent news, Moderna has seen a flurry of developments. Argus increased its price target on Moderna to $150, following the FDA's approval of Moderna's mRESVIA, an mRNA respiratory syncytial virus (RSV) vaccine for adults aged 60 and over. This vaccine is the first mRNA vaccine approved for a disease other than COVID-19, marking a significant milestone for Moderna. Meanwhile, TD Cowen maintained a Hold rating on Moderna shares with a consistent price target of $75.00, following discussions about the recent approval of their RSV vaccine and the anticipated launch of mRESVIA.
Moderna also reported successful results from the Phase 3 trial of its mRNA-1283 vaccine, which met its primary efficacy endpoint. The vaccine demonstrated efficacy against COVID-19 when compared to the company's previously authorized vaccine, Spikevax. On the other hand, Jefferies reiterated a Buy rating on Moderna shares with a price target of $180, following the release of Phase III data for Moderna's combined Covid-19 and influenza vaccine.
Moreover, Moderna's investigational mRNA-1083 vaccine, designed to target both influenza and COVID-19, achieved its primary endpoints in a Phase 3 trial. The vaccine elicited stronger immune responses compared to the currently licensed flu and COVID-19 vaccines in adults aged 50 and above. These developments highlight Moderna's continued efforts to innovate in the vaccine space, with the successful progress of its vaccine pipeline being closely watched by investors and healthcare professionals alike.
InvestingPro Insights
As Moderna, Inc. (NASDAQ:MRNA) experiences notable insider transactions, investors are keenly observing the company's financial health and market performance. InvestingPro data reveals a market capitalization of $51.24 billion, indicating the company's substantial footprint in the biotechnology sector. Despite a challenging environment with a significant sales decline of -65.78% over the last twelve months as of Q1 2024, Moderna's stock has shown resilience with a strong return of 28.16% over the last three months, and an even more impressive 46.34% over the last six months.
Reflecting on the company's balance sheet strength, one of the InvestingPro Tips highlights that Moderna holds more cash than debt, which could provide a cushion against market downturns and investment in future growth. Additionally, while analysts anticipate a sales decline in the current year, the company has demonstrated the ability to navigate through volatile market conditions with a significant price uptick over the last six months.
The company's P/E ratio stands at -8.55, which may raise questions about its earnings outlook. However, it's worth noting that Moderna has been aggressively buying back shares, as per another InvestingPro Tip, which could be a sign of management's confidence in the company's intrinsic value and future prospects.
Investors looking for comprehensive analysis and additional insights can find a total of 13 InvestingPro Tips on Moderna, which can be accessed through InvestingPro's platform. For those interested in a deeper dive into Moderna's financial and market performance, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.